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Dr Jules Lin (Ann Arbor, Mich).DrNguyen, congratulations on
your work and an excellent presentation.
You have identified potential therapeutic targets for MPM in the
Hh pathway, SMO and Gli, and identifying a novel target is a good
first step. We are often frustrated by the lack of inhibitors, and this
approach you have taken is exciting, to find a commonly used drug
that has been extensively tested in humans that happens to inhibit
the targets you have identified to treat MPM.
I have 3 questions for you. ITRA has many different effects, and
it affects other pathways, including the mammalian target of rapa-
mycin pathway. Did you confirm that the effects that you see here
are from the inhibition of the Hh pathway? For example, did you
inhibit a downstream mediator, such as Gli, with a small hairpin
RNA to see whether that eliminates the effect of ITRA?
Dr Nguyen. That is a very good point. ITRA has been shown to
target the mammalian target of rapamycin in signaling of the
vascular endothelial growth factor receptors in endothelial cells.
I did a lot of searching. I could not really find good studies on
the effect of ITRA in cancer cells. It will be the next step for us
to determine what ITRA does in cancer cells. Your comment about516 The Journal of Thoracic and Cardiovascular Surgselectively targeting an Hh pathway component such as Gli to
determine the relative contribution of Hh inhibition in mediating
the growth inhibitory effect of itraconazole is valid. In this case,
I would knockdown SMO because it is the target of ITRA. I agree
with you that ITRA has other effects that inhibit cancer cell
growth. The antiproliferation effect we observed might not all be
coming from SMO inhibition. Also, even if the anticancer effect
is SMO independent, we can always use Gli knockdown as a
marker of the drug effect on the cells. That is a very good point.
Dr Lin.My second question is, in basal cell carcinoma, as you
mentioned, PTCH was decreased and that was the mechanism for
Hh overexpression in the basal cells. In MPM, what is the
exact alteration? In your cell lines, did you see certain genes that
were overexpressed and that correlated with the treatment
response? Which would be the best biomarker for the treatment
response?
Dr Nguyen. I appreciate those comments a lot. A recently
published study in the International Journal of Oncology
(2012;41:1751-61) examined the antiproliferation effect of
cyclopamine—a prototypic SMO inhibitor—in a large collection
of cancer cell lines of epithelial origin. The investigators screened
for activating mutations of PTCH or SMO, and they observed
none. It only seems to occur in basal cell carcinoma or medullo-
blastoma. However, the Hh pathway can be activated by other
mechanisms, including overexpression of the ligands. More
importantly, evidence has shown that the Hh pathway can be acti-
vated by a paracrine effect with ligands coming from the tumor
microenvironment (low Hh activity in in vitro cultures but high
levels of activation in tumor xenografts). We do not see that in
the in vitro system. The other report has shown that the method
we use to grow cells can affect Hh signaling. We grow cells as a
monolayer on plastic ware. So, my next step would be to study
cells grown as spheroids. Other investigators have shown that in
the spheroid-grown condition, pathways such as Notch, Wnt, or
Hh are activated. Thus, that would be another way of looking at
it. What you referred to in your last question is the identification
of a biomarker or gene signature predictive of the treatment
response. That is the next step of our research project. I appreciate
that insightful comment.
Dr Lin. Then, my final question, Dr Jablons’ group at the Uni-
versity of California, San Francisco, found that Gli2 was overex-
pressed, and they thought that resulted from a SMO-independent
pathway, perhaps transforming growth factor-b. Did you consider
that at all, and did you find any synergistic effects if you inhibited
both SMO and Gli at the same time?
Dr Nguyen. Can you repeat that question?
Dr Lin. Did you find any synergistic effects if you inhibited
both SMO and Gli simultaneously?
Dr Nguyen. Yes. A report was published by Beachy’s group
from Stanford studying combining ITRA and ATO (Cancer Cell.
2013;23:23-34). Yes, that would be something that we can do, is
to combine, targeting different levels of the pathway. As you
know, when you treat cells with GDC, SMO mutants emerge
that are resistant to the drug. We must find a method to overcome
that. One way of doing it would be to target downstream of SMO,
such as at the Gli level.
Dr Lin. Congratulations on your work.ery c January 2014
